LAVAL, QC, April 27, 2017 /CNW/ - BELLUS Health Inc. (TSX:
BLU) (BELLUS Health or the Company), a biopharmaceutical
development company advancing novel therapeutics for conditions
with high unmet medical need, today announced that Roberto Bellini, BELLUS Health's President and
Chief Executive Officer, will present a corporate overview of the
Company, including the recently in-licensed BLU-5937 program for
chronic cough, on Monday May 1, 2017
at 11:30 am Eastern Time at the 2017
Bloom Burton & Co. Healthcare Investor Conference which will be
held at the Sheraton Centre Toronto Hotel.
A live audio webcast and archive of the event will be available
at: http://wsw.com/webcast/bloomburton2/blu.to. To ensure a timely
connection to the webcast, it is recommended that users register at
least 15 minutes prior to the scheduled start time. An
archived version of the webcast and BELLUS Health's corporate
presentation will be available on the Company's website at
www.bellushealth.com following the presentation.
The Bloom Burton & Co. Healthcare Investor Conference brings
together Canadian, U.S. and international investors who are
interested in the latest developments in the Canadian healthcare
sector. Attendees will have an opportunity to obtain corporate
updates from the premier Canadian publicly traded and private
companies through presentations and private meetings.
About BELLUS Health (www.bellushealth.com)
BELLUS Health is a biopharmaceutical development company
advancing novel therapeutics for conditions with high unmet medical
need. Its pipeline of projects includes BLU-5937 for chronic cough
and several other partnered clinical-stage drug development
programs.
Forward-Looking Statements
Certain statements contained in this news release, other than
statements of fact that are independently verifiable at the date
hereof, may constitute "forward-looking statements" within the
meaning of Canadian securities legislation and regulations. Such
statements, based as they are on the current expectations of
management, inherently involve numerous important risks,
uncertainties and assumptions, known and unknown, many of which are
beyond BELLUS Health Inc.'s control. Such risks factors include but
are not limited to: the ability to expand and develop its project
pipeline, the ability to obtain financing, the impact of general
economic conditions, general conditions in the pharmaceutical
industry, changes in the regulatory environment in the
jurisdictions in which BELLUS Health Inc. does business, stock
market volatility, fluctuations in costs, changes to the
competitive environment due to consolidation, achievement of
forecasted burn rate, potential payments/outcomes in relation to
indemnity agreements and contingent value rights, achievement of
forecasted pre-clinical and clinical trial milestones and that
actual results may vary once the final and quality-controlled
verification of data and analyses has been completed. In addition,
the length of BELLUS Health Inc.'s drug candidates development
process, their market size and commercial value, as well as the
sharing of proceeds between BELLUS Health Inc. and its potential
partners from potential future revenues, if any, are dependent upon
a number of factors. Consequently, actual future results and events
may differ materially from the anticipated results and events
expressed in the forward-looking statements. The Company believes
that expectations represented by forward-looking statements are
reasonable, yet there can be no assurance that such expectations
will prove to be correct. The reader should not place undue
reliance, if any, on any forward-looking statements included in
this news release. These forward-looking statements speak only as
of the date made, and BELLUS Health Inc. is under no obligation and
disavows any intention to update publicly or revise such statements
as a result of any new information, future event, circumstances or
otherwise, unless required by applicable legislation or regulation.
Please see BELLUS Health Inc.'s public filings with the Canadian
securities regulatory authorities, including the Annual Information
Form, for further risk factors that might affect BELLUS Health Inc.
and its business.
SOURCE BELLUS Health Inc.